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ATP productionMetabolic stimuli such as insulin and insulin like growth factor cause cellular accumulation of G protein
coupled receptor kinase 2 (GRK2), which in turn is able to induce insulin resistance. Here we show that in
ﬁbroblasts, GRK2 is able to increase ATP cellular content by enhancing mitochondrial biogenesis; also, it an-
tagonizes ATP loss after hypoxia/reperfusion. Interestingly, GRK2 is able to localize in the mitochondrial outer
membrane, possibly through one region within the RGS homology domain and one region within the catalyt-
ic domain. In vivo, GRK2 removal from the skeletal muscle results in reduced ATP production and impaired
tolerance to ischemia. Our data show a novel sub-cellular localization of GRK2 in the mitochondria and an un-
expected role in regulating mitochondrial biogenesis and ATP generation.39 089969642.
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An emerging and intriguing role of the G protein coupled receptor ki-
nase 2 (GRK2) involves its ability to modulate themetabolic state of the
cell. Little is known about this feature, opposite to the relevance of the ki-
nase in the regulation of the G protein coupled receptor (GPCR) signal-
ing. Indeed, GRK2 belongs to a family of seven serine/threonine protein
kinases, each encoded by a single gene, that speciﬁcally phosphorylates
the activated form of GPCRs, mediating their desensitization [1,2].
The ﬁrst suggestion that GRK2 is involved in the cellular metabo-
lism derives from the observation that insulin [3] and insulin like
growth factor are both able to induce up regulation of the kinase,
which occurs within the time frame of a few minutes. Interestingly,
GRK2 accumulation leads to the shut-off of insulin signaling and in-
hibits glucose extraction [3–5]. Conditions characterized by elevated
GRK2 levels such as hypertension or chronic activation of β adrener-
gic receptor [3], as well as transgenic overexpression of the kinase [6]
present resistance to the metabolic effects on the cell induced by in-
sulin. This evidence suggests a novel role of GRK2 in controlling the
cellular use of glucose and, more in general, the ability of the cell to
master energy production and expenditure.Mitochondria, of course, play an important role in cell energy produc-
tion, given their ability to produce ATP in an oxygen dependent manner.
The mitochondria functional state varies dramatically depending on the
functional andmetabolic state of the cell. Post transductionmodiﬁcation
of mitochondrial proteins and in particular protein phosphorylation ap-
pears to be an important mechanism of mitochondrial function. In the
last few years, different reports [7] conﬁrmed that a series of kinases
(MAPKs, Akt, PKA and PKC) are present in mitochondria, particularly in
the intermembrane space and membranes where they meet mitochon-
drial constitutive upstream activators.
All of the above considerations prompted us to verify the hypothesis
that GRK2 might affect energy cellular production by interfering with
mitochondrial function. Pursuing this aim, we demonstrate that GRK2
has capability to localize in the mitochondrial fraction and profoundly
affect the biology and the production of energy of these organelles.
2. Materials and methods
2.1. Cell culture
HEK-293 cells were cultured in Dulbecco's minimal essential medium
(DMEM) and 25 mMglucose supplementedwith 10% fetal bovine serum
(FBS) at 37 °C in 95% air and 5% CO2.
2.2. Primary cultured mouse aorta cells and infection
Primary cultured cells were prepared with little modiﬁcations
from a previously validated protocol [8] for extraction of cells from
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mozygous GRK2f/f) [9,10]. Brieﬂy, vessels were cut in rings and placed
on Matrigel (BD Technologies), incubated in Dulbecco's minimal es-
sential medium (DMEM) supplemented with 20% fetal bovine
serum (FBS) and incubated at 37 °C in 95% air and 5% CO2. After 5 to
7 days, aortic rings were removed, and the cells remaining on Matri-
gel expanded. To obtain GRK2 knock out cells, we incubated GRK2f/f
primary cultured cells with an adenovirus encoding for Cre recombi-
nase (AdCre, Vector Biolabs) at MOI of 50 particles per cell for 3 h in a
serum free medium. Incubation was repeated after 1 week. GRK2 re-
moval was conﬁrmed by western blot. A similar procedure, using an
empty vector (AdEMPTY, Vector Biolabs) was applied to obtain con-
trol GRK2f/f cells. Cells were studied between passages 7 and 14.
2.3. GRK2 cloning in pcDNA3.1
Using human GRK2 cDNA (GRK2-WT) in pcDNA3.1 [3] as a tem-
plate and the primers which contain consensus sequences for the in-
dicated restriction enzymes (Table 1), we ampliﬁed the N-Terminal
region and catalytic domain, (GRK2 NT-CD, 1–453 amino acids), the
catalytic domain and C-Terminal region (GRK2 CD-CT, 191–689
amino acids), the C-Terminal region (GRK2 CT 454–689 amino
acids) and the RH domain (GRK2 RH, 54–174 amino acids) (Fig. 3A).
These truncated mutants were cloned in pcDNA3.1 (+) Myc/His A
by means of T4 DNA ligase (Promega). The right frame and orienta-
tion were conﬁrmed by restriction analysis and DNA sequencing by
using the above indicated primers (Avant 3100, Applied Biosystem).
2.4. Cell transfections
Cell trasfection was performed with lipotrasfection reagents (lipofec-
tamine 2000, Invitrogen) using 2 μg of plasmid DNA according to manu-
facturer's instructions [3,11]. For stable transfected clone selections, after
24 to 48 h cell medium was supplemented with G418 (500 μg/mL) for
2 weeks. The G418-resistant cells were cultured in medium supplemen-
ted with G418 to a ﬁnal concentration of 250 μg/mL and examined for
overexpression of GRK2 (GRK2-HEK) by western blotting, using speciﬁc
antibodies (Santa Cruz Biotechnology).
2.5. Mitochondria extracts preparation and western blot
Cells were washed in ice-cold phosphate buffer (PBS) and dis-
rupted by dounce homogenization in isolation buffer [IB pH 7.4
200 mM sucrose, 1 mM EGTA-Tris and 10 mM Tris-MOPS]. The ho-
mogenate was spun at 800 g for 10 min; the supernatant was recov-
ered and further centrifuged for 10 min at 8000 g. The resultingTable 1
Primer sequences used for ampliﬁcation of truncated mutants of human GRK2 gene.
Truncated
mutants
Primers Restriction
enzymes
GRK2 NT-CD For: 5′-TAAGCTTGGATGGCGGACCTGGAGGC-
3′
HindIII
Rev: 5′-
CCCTCTAGAGAAAAAGGGGCTCTCTTTC-3′
XbaI
GRK2 CD-CT For: 5′-
TAAGCTTGGATGGAATGACTTCAGCGTGCATC-3′
HindIII
Rev: 5′-
CCCTCTAGAGAGGCCGTTGGCACTGCCGCG-3′
XbaI
GRK2 RH For: 5′-
AAAAGGATCCTGATGACCTTTGAGAAGATC-3′
BamHI
Rev: 5′-
AAAAGATATCTGCAAAACCGTGTGAACTTATC-3′.
EcoRV
GRK2 CT For: 5′-
TAAGCTTGGATGCTCCCTGGACTGGCAGATG -3′,
HindIII
Rev: 5′-
CCCTCTAGAGAGGCCGTTGGCACTGCCGCG- 3′
XbaIpellet (mitochondrial fraction) was collected while the supernatant
was further spun for 30 min at 100,000 g to obtain the cytosolic frac-
tion, spanned again at 100,000 g to further purify the fraction. The mi-
tochondrial fraction was further puriﬁed by centrifuging twice at
8000 g for 10 min. The obtained pellet was puriﬁed by centrifugation
at 95,000 g for 30 min on a 30% Percoll gradient in IB [12]. The
obtained mitochondrial layer was washed free of Percoll and resus-
pended in IB. Protein concentration was determined by bichinconnate
assay (Pierce). Cytosol and mitochondria extracts were conﬁrmed by
western blot using speciﬁc antibodies (Santa Cruz Biotechnology).
Cellular or mitochondria extracts were electrophoresed by SDS/PAGE
and transferred to nitrocellulose; GRK2 was visualized by speciﬁc anti-
body (Santa Cruz Biotechnology), anti-mouseHRP-conjugated secondary
antibody (Santa Cruz Biotechnology) and standard chemiluminescence
(Pierce) on autoradiographic ﬁlm. Images were then digitalized and den-
sitometric analysis was performed (ImageQuant software).
2.6. Overlay assay
Mitochondrial proteins were electrophoresed by SDS/PAGE and
transferred to nitrocellulose. The membrane was incubated with
50 ng of GRK2 puriﬁed protein (Invitrogen) in binding buffer [Hepes
0.25 M; MgCl2 50 mM; DTT 2.5 mM; Na3VO4 5 mM; H20-Tween
0.1%] for 1 h at room temperature. Protein was ﬁxed in 0.5% formalde-
hyde for 5 min and washed with 2% glycine [13]. GRK2 was visualized
by chemiluminescence after incubation with anti-GRK2 antibody
(Santa Cruz Biotechnology).
2.7. Kinase assay
Kinase assay was performed by using mitochondrial extracts. Phos-
phorylation reaction was initiated by adding master mix (Hepes
0.5 M; MgCl2 1 M; DTT 1 M; Na3VO4 1 M; H20-Tween 0.1%), 50 ng of
GRK2 puriﬁed protein (Invitrogen) and [γ-32P]ATP (GE Healthcare)
and prolonged for 30 min at 37 °C. Laemmli buffer was added to stop
the reaction. Then, 30 μl of the reaction mix were resolved on SDS-
PAGE4-12% gradient (Invitrogen), stained with Coomassie blue, de-
stained, vacuum dried, and exposed for autoradiography [14].
2.8. Quantitative analysis of mitochondrial nucleic acids
Cell DNA and total RNAwere isolated using commercially available re-
agents (DNAzol and Trizol, Invitrogen). cDNA was synthesized from RNA
by reverse transcriptase (Invitrogen), following the manufacturer's in-
structions. Real-time quantitative polymerase chain reaction (RT-PCR)
was performed on DNA and cDNA as previously described [11] to amplify
two mitochondrial (cytochrome b, NADHd), and one nuclear (β globin)
genes. The primer sequences used were: [15] cytochrome b: For: 5′-
CCTAGGCGACCCAGACAATTAT; Rev: 5′-TCATTCGGGCTTGATGTGG;
NADHd: For: 5′-CAGCCATTCTCATCCAAACC; Rev: 5′-ATTATGATGC-
GACTGT GAGTGC; β globin: For: 5′-AGCCTGACCAACATGGTGAAAC; Rev:
5′-AGCCACCTGAATAGCTGGGACT. All values obtained were normalized
to the values obtainedwith the β globin primers. The reactionwas visual-
ized by SYBR Green Analysis (Applied Biosystem) on StepOne instrument
(Applied Biosystem). The results are expressed as the relative integrated
intensity.
2.9. Immunoﬂuorescence
HEK-293 and GRK2-HEK cells were incubated for 30 min with 5 nM
mitotracker (Rosamine-basedMitotracker dye-Invitrogen) to identifymi-
tochondria. Then the cellswereﬁxedwith−20 °C coldmethanol/acetone
and permeabilized by incubation in 0.3% Triton X-100 solution for
3 min. Cells were incubated for 1 h at room temperature with mouse
anti-GRK2 Ab (Santa Cruz Biotecnology) in PBS containing 1% BSA
[14]. After two washings in PBS, the cells were incubated for 1 h at
Fig. 1. (A) Cellular and mitochondrial ATP content in HEK-293 and GRK2-HEK cells.
(* pb0.05 vs HEK-293 cells). (B) Infection with AdCRE removes GRK2 gene in GRK2f/f
cells. Recombinant ﬂoxed GRK2 cells were incubated either with adenovirus encoding
for Cre recombinase (AdCRE, Vector Biolabs) or an empty virus (AdEMPTY) at MOI of 50
particles for 3 h in a serum free medium. Cells were then maintained in culture and
GRK2 removalwas conﬁrmedbywesternblot (1: cells treatedwithAdCRE; 2: cells treated
with AdEMPTY). (C) Cellular and mitochondrial ATP content in GRK2f/f and GRK2f/f,CRE
aortas derived cells. (+ pb0.05 vs GRK2f/f cells).
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trogen) in PBS. After washing in PBS, the glass slides were mounted
under a coverslip in a 50% glycerol PBS solution. Images were acquired
with a Zeiss 510 confocal laser scanning microscope.
2.10. Transmission electron microscopy (TEM) and Immunogold staining
Mitochondrial fractionswerewashed in PBS and ﬁxed in 4% parafor-
maldehyde for 4 h at 4 °C. Then samples were incubated with 0.05 M
glicine, dehydrated in graded ethanols and 100% acetone and blocked
in 5% BSA in PBS for 1 h. Mitochondrial fractions were washed in incu-
bation buffer (IB: 0.8% BSA in PBS and 15 mM NaN3), incubated with
anti GRK2 antibody (5 μg/ml) in IB overnight and washed in IB. Subse-
quently, samples were incubated with secondary antibody (Aurion
ultra-small gold reagents) for 1.5 h, washed and incubated with Aurion
R-gent SE-EM, according to manufacturer's instructions. Samples were
then ﬁxed with 2.5% glutaraldehyde, washed in PBS, ﬁxed in osmium
tetroxide, dehydrated in an ethanol series, embedded in epoxy
resin, and then examined under a transmission electron microscope
(JEM-2000EX), at the Federico II facility for advanced imaging (CISME).
2.11. Cytoﬂuorimetry
Cells were incubated for 30 min with 5 nMmitotracker (Rosamine-
basedMitotracker dye-Invitrogen) to identifymitochondria. Thenmito-
tracker stained and unstained control cells were analyzed by ﬂow cyto-
metry (FACSCalibur, BD Biosciences) followed by analysis of mean
ﬂuorescence intensity of 10,000 events by Cellquest software (BD Bio-
sciences) [16].
2.12. Assay for oxidative ATP synthesis
Cellswere harvested, washed twice in PBS, and counted in a Burker's
camera. A replicate for each samplewas prepared that had been treated
for 1 h with 4 μg/ml rotenone (Sigma). The emission recorded from
samples treated with rotenone was deﬁned as baseline luminescence
corresponding to a non mitochondrial source of ATP. Assays were per-
formed using the ATP luminescence assay kit (Sigma) according to
manufacturer's instructions.
2.13. Cell hypoxia
Cell medium was previously saturated for 10 min at 1 atm with 95%
N2 and 5% CO2 mixture, containing (mM) concentrations of 116NaCl,
5.4KCl, 0.8MgSO4, 26.2NaHCO3, 1NaH2PO4, 1.8CaCl2, 0.01glycine and
0.001 (%w/v) phenol red, and placement in an anaerobic chamber (hyp-
oxia chamber) ﬁlledwith the same gasmixture and heated to 37 °C. The
pH, PO2 and PCO2 of the resulting medium were 7.36±0.2, 45.3±
1.2 mmHg, and 35.3±0.8 mm Hg and 7.32±0.9, 32.6±1.1 and
37.9 ±2.1 mm Hg, before and at the end of hypoxia, respectively [17].
2.14. Mouse skeletal muscle infection
Animal studies were carried out on homozygous GRK2f/f mice [9]
(n=23; weight: 26.7±3.1 g) in accordance to Federico II University
guidelines. To obtain GRK2 gene removal, mice were anaesthetized
by vaporized Isoﬂurane 3% and intramuscular injection of AdCre
(109 pfu/ml) were performed into right quadriceps femoris (200 μl)
muscle. GRK2 removal was conﬁrmed by western blot. After 5 days
we performed ischemia/reperfusion.
2.15. Mouse surgery
Mice were anaesthetized by isoﬂurane 4% inhalation and maintained
by mask ventilation (isoﬂurane 2%). A surgical incision was made in the
skin overlying the middle portion of the right hind limb and the rightcommon femoral artery was exposed and isolated, as previously de-
scribed [18], and a slipknotwas placed around the proximal endof the ar-
tery with a 5–0 silk suture, maintained for 1 h to induce hind limb
ischemia. Groups of 3 mice were sacriﬁced at the end of 1 h of ischemia,
after 15 min or 60 min of reperfusion. These mice were compared to
GRK2f/f mice subjected to the same procedures (3 for each time point)
and to sham-operated GRK2f/f (n=3) and GRK2f/f,Cre (n=3).
2.16. Assay for oxidative ATP synthesis in vivo
At sacriﬁce, quadriceps femoris muscles were harvested and
quickly washed in PBS. Assay was performed using the ATP lumines-
cence assay kit (Sigma) according to manufacturer's instructions.
Then, values were normalized according to muscles' weights.
2.17. Statistical analysis
All values are presented as mean±SEM. Two-way ANOVA was
performed to compare the different parameters among the different
groups. Bonferroni post hoc testing was performed where applicable.
A signiﬁcance level of pb0.05 was assumed for all statistical evalua-
tions. Statistics were computed with GraphPad Prism software (San
Diego, California).
3. Results
3.1. GRK2 increases oxidative ATP synthesis
To evaluate the relevance of GRK2 in energy production we mon-
itored whether GRK2 modulates mitochondrial ATP synthesis. Fig. 1A
shows that human embryonic kidney (HEK-293) ﬁbroblasts stably
over expressing a human GRK2 gene (GRK2-HEK) contain higher
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also studied primary cultured cells derived from the aortas of recom-
binant mice with both copies of the GRK2 gene ﬂanked by two f-lox
sites (GRK2f/f). When these cells were infected with AdCre to obtain
cellular expression of the bacterial CRE recombinase (GRK2f/f,CRE),
GRK2 protein levels became undetectable (Fig. 1B). At the same
time, in GRK2f/f,Cre cells (Fig. 1C) there is a signiﬁcant reduction of
total and mitochondrial ATP levels, supporting a positive role of
GRK2 in bio-energetic pathway.Fig. 2. (A) Mitochondria were obtained by co-fractionation experiments on a 30% Percoll grad
nogold on mitochondria extracts using anti-GRK2 antibody. (C) GRK2 levels were analyzed in
absence of Histone H3 and Calnexin in puriﬁedmitochondria was conﬁrmed by western blot in
expression of GRK2-WT increases GRK2 levels both in cytosol and mitochondria (*pb0.05 vs H
mitochondrial integrity, triton X-100 (Trit) was added in the digestion buffer. Samples were p
orescence. HEK-293 cells (upper lane) andGRK2-HEK cells (lower lane)were labeled in vivowi
were taken under confocal microscopy. Bars, 10 μm.3.2. GRK2 is located in mitochondria
To clarify the basis for the possible link between GRK2 and the mi-
tochondria, we evaluated the presence of the kinase in the organelles
by co-fractionation experiments on a 30% Percoll gradient. First of all,
to verify that the mitochondrial fraction was free from contaminants
of other compartments, we observed samples from HEK-293 cells
under TEM and conﬁrmed the purity of the mitochondrial fraction
(Fig. 2A). On this fraction, immunogold analysis shows that the kinaseient and observed by electron microscopy. (B) GRK2 localization was observed by immu-
cytosol (Cyt) and mitochondrial (Mit) extracts by western blot in HEK-293 cells. (D) The
HEK-293 cells, using cellular extracts for molecular weight reference. (E) The stable over-
EK-293 cells). (F) Mitochondria were incubated with or without tripsin (Trip). To disrupt
robed for GRK2, Mn SOD and VDAC1. (G) GRK2 localization was analyzed by immunoﬂu-
thmitotracker (red),ﬁxed, and immunostainedwith anti-GRK2 (green) antibody. Pictures
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membranes (Fig. 2B).
Localization of GRK2 on mitochondria was also conﬁrmed on mi-
tochondria and cytosol fractions isolated from HEK-293 cells by west-
ern blot. Fig. 2C shows that endogenous GRK2 partly co-puriﬁed with
the mitochondria-enriched fraction, as did the Mn-dependent Super-
oxide Dismutase (Mn SOD), a protein that resides within mitochon-
drial compartments. We veriﬁed that the puriﬁed mitochondrial
fractions were free from contaminants of the cytosol (actin)
(Fig. 2C), nuclei (Histone H3) and sarcoplasmic reticulum (calnexin)
(Fig. 2D). The speciﬁcity of the antibody for GRK2 is conﬁrmed by
the observation that stable overexpression of GRK2 in HEK-293 cells
increases the levels of the protein both in cytosol and mitochondria
(Fig. 2E).
To conﬁrm the sub-mitochondrial compartment where GRK2 lo-
calizes, we subjected the puriﬁed mitochondrial fraction to a double
treatment with trypsin and triton demonstrating that the kinase tar-
gets to outer membrane (Fig. 2F). Conﬁrmation derives from the evi-
dence that the mitochondrial outer membrane protein VDAC1 but not
the mitochondrial matrix protein MnSOD localizes in the same sub-
mitochondrial fraction as GRK2.
Finally, the ability of GRK2 to co-localize with mitochondria was
also demonstrated by confocal microscopy using immunoﬂuores-
cence (Fig. 2G). In particular, imaging conﬁrms the ubiquitous locali-
zation of GRK2 within the cytosol and the membrane compartments,
but the nucleus. When the GRK2 and mitochondria signals are
merged, it appears clearly that GRK2 can compartmentalize in mito-
chondria. This feature is further highlighted in presence of GRK2
overexpression (Fig. 2G).Fig. 3. (A) GRK2 sequence and truncated mutants cloned in pcDNA3.1 (+) Myc/His A. HEK-
GRK2 CD-CT (D) and GRK2 CT (E).3.3. Two regions within GRK2 sequence show afﬁnity for mitochondria
To map the regions of GRK2 that possess the ability to localize in mi-
tochondria, we generated myc/histidine-tagged, truncated mutants of
GRK2 (Fig. 3A). The aminoacid sequence 1–453 is able to localize tomito-
chondria (Fig. 3B). Within this region, we found that the 120 aminoacids
comprising the RGS homology (GRK2 RH) domain (aminoacids 54–174)
are able to target mitochondria (Fig. 3C). Also, the region 191–689
(Fig. 3D) which comprises the catalytic and carboxyl termini (CT)
domain is able to target the mitochondria. Finally, the CT sequence per
se (495–689, Fig. 3E) cannot bind the organelles.
3.4. GRK2 interacts and phosphorylates unidentiﬁed mitochondrial proteins
To conﬁrm the ability of GRK2 to localize on mitochondria, we
performed an overlay assay with puriﬁed GRK2 as bait on HEK-293
and GRK2-HEK cells mitochondria extracts blotted on nitrocellulose.
This assay conﬁrms the ability of GRK2 to interact with yet unidenti-
ﬁed mitochondrial proteins within the molecular weight range of 30–
60 KDa (Fig. 4A).
Using a similar approach, we performed a kinase assay to verify
whether GRK2 recognizes substrates among the mitochondrial pro-
teins (Fig. 4B). This experiment conﬁrms that GRK2 phosphorylates
mitochondrial proteins within the molecular range of 30–60 KDa.
3.5. GRK2 increases mitochondrial biogenesis
Given the localization of GRK2 on mitochondria, we asked wheth-
er GRK2 promotes mitochondrial DNA accumulation. By quantitative293 cells were transfected with pcDNA3.1 encoding for GRK2 NT-CD (B), GRK2 RH (C),
Fig. 4. (A) Overlay assay with (left blot) or without (right blot) puriﬁed GRK2 as bait in
HEK-293 and GRK2-HEK cells mitochondria blotted on nitrocellulose. (B) Puriﬁed
GRK2 was incubated with HEK-293 and GRK2-HEK mitochondrial extracts blotted on
nitrocellulose in a kinase buffer, in presence of [32P]γ-ATP. The blot was then exten-
sively washed and exposed to autoradiography.
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NADH de-hydrogenase (NADHd) and cytochrome B (Cyt B), using nu-
clear β globin gene as internal control. Fig. 5A shows that GRK2 in-
creased the levels of both mitochondrial genes.
To correlate the increased mitDNA with increased expression of mi-
tochondrial proteins, we monitored the expression levels of NADHd
and cytochrome B mRNA. Total RNA was extracted from cells and sub-
jected to reverse transcription and quantitative RT-PCR analysis. As
shown in Fig. 5B, GRK2 signiﬁcantly up-regulated the levels of NADHd
and cytochrome BmRNAs. Reciprocally, in GRK2f/f,CRE cells, we observed
a reduction in the number of copies and the level of expression of the
NADHd and cytochromeB as compared to GRK2f/f cells (Figs. 5C and 5D).
To assess the actual change in total mitochondrial mass, we loaded
cells with the mitochondrial selective ﬂuorescent dye mitotracker
and analyzed the intensity of ﬂuorescent emission by FACS analysis.
GRK2 overexpression in HEK-293 induced a rightward shift in theemission proﬁle of mitotracker, which increased by a 36% (Fig. 5E).
Reciprocally, in GRK2f/f,Cre cells, we observed a leftward shift com-
pared to GRK2f/f cells, accounting for a decrease of emission intensity
of mitotracker of about 31% (Fig. 5F). These data are compatible with
a positive effect of GRK2 on mitochondrial biogenesis.
3.6. GRK2 protects from hypoxia/reperfusion induced ATP loss
Given the ability of GRK2 to promote ATP production through an in-
crease in mitochondria, we veriﬁed the effects of the kinase in a mito-
chondrial threatening condition, the hypoxia/reperfusion. Acute hypoxia
(1 h) promotes an increase of total and mitochondrion-associated GRK2
levels, as assessed by western blot analysis. The increase of GRK2 levels
in hypoxic conditions was transient, since re-oxygenation for 15 min
and 1 h restored the levels of the kinase to normal oxygen conditions
(Fig. 6A). In control cells, ATP levels decreased during hypoxia and after
oxygen restoration. Over-expression of GRK2 attenuated the loss of ATP
production, compared to controls (Fig. 6B). As expected, in GRK2f/f,CRE
cells ATP levels were severely reduced under both basal and hypoxia con-
ditions, and the recovery following oxygen restoration was impaired
(Fig. 6C).
3.7. Removal of GRK2 gene in GRK2f/f,CRE mice decreases ATP levels
We evaluated the role of GRK2 in the regulation of ATP levels in an
in vivo model of muscle ischemia. We used mutant GRK2f/f mice. In-
tramuscular injection of adenoviral particles (109 pfu/ml) encoding
for Cre recombinase promoted targeted deletion of GRK2 gene, thus
reducing the levels of the kinase by several folds (Fig. 6D). Ischemia
causes GRK2 mitochondrial accumulation in mouse hind limbmuscle.
Ischemia was obtained by ligation of the femoral artery for 1 h, and
reperfusion was applied for 15 min. By western blot, ischemia in-
duces an increase of GRK2, which promptly recovers to basal levels
after 15 min of reperfusion (Fig. 6E). In control GRK2f/f mice, femoral
artery occlusion reduced ATP levels, in quadriceps femoral muscle.
Reperfusion of ischemic muscles for 15 min and 1 h partially restored
muscular ATP levels. In GRK2f/f,CRE muscles, GRK2 removal parallels a
signiﬁcant reduction of ATP levels. GRK2 deletion also attenuated the
recovery of ATP levels following reperfusion of ischemic muscles,
compared to GRK2f/f mice (Fig. 6F).
4. Discussion
This report shows for the ﬁrst time that GRK2 can localize on
the mitochondrial outer membrane. Indeed, until now, the paradigm
indicates that GRK2 shuttles between the cytosol and the plasmamem-
brane, anchoring to the latter through its pleckstrin homology andGβγ
binding domains within the carboxyl terminus [19]. Our data allow us
to indicate that also the mitochondria should be included as a cellular
compartment on which this molecule can be found. Two regions
within the RH and the catalytic domains possess the ability to localize
truncated mutants of GRK2 on these organelles. The most compelling
ﬁnding, though, is that GRK2 modiﬁes the biology of mitochondria.
Indeed, the mitochondrial compartment is more than just a reservoir
for the kinase. We observed consensual changes in mitochondrial
DNA and RNA, as well as mitochondrial mass size, after overexpression
or deletion of GRK2, consistent with the ability of the kinase to pro-
mote mitochondrial biogenesis. Furthermore, these changes are paral-
leled by modiﬁcation of mitochondrial ATP production.
Mitochondria are most important in the settings of the responses
to stress, such as the ischemia/reperfusion [20], and under these con-
ditions we report two striking novel and unexpected observations.
First, ischemia causes acute cellular and mitochondrial accumulation
of GRK2 both in vitro (Fig. 6A) and in vivo (Fig. 6E), an effect reverted
by oxygen restoration. This surprising evidence further strengthens
the physiological role of GRK2 in the mitochondria. Second, a
Fig. 5. (A and B) Quantitative RT-PCR analysis in HEK-293 and GRK2-HEK cells of copy numbers and gene expression of the mitochondrial genes Cytochrome B (Cyt B) and NADHd,
relative to the nuclear gene β globin. (RQ: relative quantities, * pb0.05 vs HEK-293 cells). (C and D) Same as above, in GRK2f/f and GRK2f/f,CRE cells. (RQ: relative quantities,
+ pb0.05 vs GRK2f/f cells). (E) Intensity of ﬂuorescent emission in HEK-293 (green) and GRK2-HEK (red) cells and mitotracker unstained control cells (purple) under FACS analysis.
(F) Same as above, in GRK2f/f(green) and GRK2f/f,CRE(red) cells and mitotracker unstained control cells (purple).
474 A. Fusco et al. / Cellular Signalling 24 (2012) 468–475protective effect of the kinase is revealed, since transgenic overex-
pression causes mitochondrial accumulation of the kinase and pro-
tects ATP production even after hypoxia/reperfusion damage.
Although we do not have evidence regarding the mechanism
through which GRK2 localizes in the mitochondria, it is evident that
within these organelles, the kinase can bind some protein counter-
parts, which can also be phosphorylated by the kinase. It is possible
to speculate that these unknown substrates favors the accumulation
within the mitochondria of GRK2 and in turn get phosphorylated. In-
deed, using a catalytic inactive mutant of GRK2 we can observe mito-
chondrial accumulation, suggesting that the enzymatic activity of the
kinase is not needed for the localization (data not shown). The iden-
tiﬁcation of the mitochondrial partner of GRK2 is actively pursued in
the lab, and will allow to better understand the mechanisms of bio-
genesis and mitochondrial protection induced by the kinase.
The favorable activity of GRK2 within the mitochondria turns out
to be protective, in particular after ischemia/reperfusion. Previous
data in the literature support a protective role of GRK2 for the cell.
First, GRK2 gene deletion is detrimental for embryonic cardiac devel-
opment [21]. Second, in adult life, cardiac selective GRK2 removal al-
ters the cardiac hypertrophy response to chronic β adrenergic
receptor stimulation, leading to an eccentric dilatation of the heart
similar to that observed in intermediate-advanced phases of heart
failure [9]. On the contrary, other data in literature, suggest a detri-
mental effect of increased GRK2 levels for the cell, and may appearin contrast to the present observation. In particular, in mice subjected
to myocardial infarction, the inducible, cardiac speciﬁc removal of
GRK2 through gene deletion results in the amelioration of survival,
reduced “at risk” ischemic area and improved cardiac performance
[22]. This apparent discrepancy could be imputed to differences in
timing and model. Indeed, we applied ischemia reperfusion for 1 h
in the skeletal muscle. It is possible that in more extensive tissue
damage in a more sensitive tissue such as the myocardium, the nega-
tive signaling properties of GRK2 prevail on the protective metabolic
effects of the kinase.
In conclusion, our data add more support to the building of a new
perspective in which GRK2 not only regulates GPCR signaling, but also
coordinates a series of metabolic responses to excessive signaling and
stress, by starting receptor desensitization [19], reducing glucose ex-
traction [3] and metabolism and activating mitochondrial biogenesis.Acknowledgments
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Fig. 6. (A) In cells, GRK2 accumulates during hypoxia and returns to basal levels after oxygen replenishment (1: no hypoxia; 2: 1 h hypoxia; 3: 15 min oxygen replenishment; 4: 1 h
oxygen replenishment). (B) Cellular ATP content in HEK-293 and GRK2-HEK cells during hypoxia (H: hypoxia; O.R.: oxygen restoration; * pb0.05 vs HEK-293 cells). (C) Cellular ATP
in GRK2f/f and GRK2f/f,CRE cells during hypoxia (H: hypoxia; O.R.: oxygen restoration; + pb0.05 vs GRK2f/f cells). (D) In vivo GRK2 expression, in quadriceps femoris muscle from
mice harboring f-loxed GRK2 gene after intramuscular injection of AdCre (109 pfu/ml) (1: AdEMPTY; 2: AdCre). (E) Ischemia induces an increase of GRK2, which promptly recovers
to basal levels after 15 min of reperfusion (1: no ischemia; 2: 1 h ischemia; 3: 15 min). (F) ATP content in quadriceps femoris muscle of mice subjected to hind limb ischemia/reperfusion
(* pb0.05 vs GRK2f/f mice; Control: non ischemic muscle; IS: 1 h ischemia; Rep: reperfusion).
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